CARM1 and pancreatic ductal adenocarcinoma: Additionally, PRMT4 limits the metabolism of glutamine in pancreatic ductal adenocarcinoma by blocking the activity of methylated malate dehydrogenase 1 (MDH1) or methylated glyceraldehyde-3-phosphate dehydrogenase, both of which hinder the development and multiplication of cancer cells in HCC glycolysis [37, 38].